What SEC filings does Harvard Apparatus Regenerative Technology Inc. submit to the SEC?

Harvard Apparatus Regenerative Technology Inc. (HRGN) submits several types of SEC filings including Form 4 (insider transactions), Form 144 (proposed insider sales), 8-K reports (material events such as earnings releases, acquisitions, leadership changes), and periodic reports — the 10-Q (quarterly) and 10-K (annual). All filings are publicly available through SEC EDGAR.

What does a Form 4 filing tell me about HRGN?

A Form 4 for HRGN discloses a transaction by a company insider — typically a director, officer, or 10%+ shareholder. It shows the source-reported date, number of shares, price, and updated ownership. These facts do not establish motive or predict future returns.

How do I interpret an 8-K filing from Harvard Apparatus Regenerative Technology Inc.?

An 8-K signals a material event requiring prompt disclosure. Common triggers include earnings pre-announcements, acquisitions, leadership appointments or departures, credit changes, or regulatory actions. Read the item codes inside the filing to understand exactly what was disclosed before drawing conclusions.

What is the difference between a 10-K and 10-Q for HRGN?

The 10-K is Harvard Apparatus Regenerative Technology Inc.'s annual report with fully audited financial statements, comprehensive MD&A, and complete risk factor disclosures — filed 60–90 days after fiscal year-end. The 10-Q is a lighter quarterly report with unaudited financials filed for the first three quarters. Together they provide a continuous financial picture of the company.

Where can I see all HRGN SEC filings directly on EDGAR?

You can view all historical Harvard Apparatus Regenerative Technology Inc. filings on the SEC EDGAR company page for HRGN. Each filing card on this page links directly to the original SEC document.

HRGN SEC Filing News — Harvard Apparatus Regenerative Technology Inc.

Q: How often does Harvard Apparatus Regenerative Technology Inc. file with the SEC?

Harvard Apparatus Regenerative Technology Inc. files one 10-K per year and up to three 10-Qs per year. Form 4 insider transactions must be reported within two business days of each trade, so the frequency depends on how often insiders are buying or selling HRGN shares. 8-K filings occur whenever a material event happens — which can be several times per quarter for an active company.

Latest SEC filings for Harvard Apparatus Regenerative Technology Inc. (HRGN) explained in plain English. Covers insider buying and selling (Form 4), proposed insider sales (Form 144), material company events (8-K), and quarterly & annual reports (10-Q / 10-K). StrongBuyAnalytics provides navigation and brief excerpts or summaries; original filings remain at the SEC/source links and were authored by their filers, not StrongBuyAnalytics. Filing dates shown are source dates. Coverage and detection can be delayed or incomplete because of SEC availability, amendments, parsing, caching, or outages. Latest source filing date shown: 2026-09-25.

Harvard Apparatus Regenerative Technology Inc., a clinical-stage biotechnology company, focuses on developing regenerative-medicine treatments for disorders of the gastro-intestinal system and other organs resulting from cancer, trauma, or birth defects. The company's lead product candidate is Cellspan Esophageal Implant for the treatment of severe esophageal disease. It's pipeline includes organ-regeneration technology for the repair or replacement of diseased or damaged organs; and product can…

Sector: Consumer Defensive Industry: Packaged Foods Market Cap: $45.2M

Total Filings

Bullish Classifications

Bearish Classifications

Insider Transactions

Material Events (8-K)

Periodic Reports

Rule-based classifications for HRGN currently lean bullish. Of the 20 displayed SEC filing records, 5 carry bullish classifications versus 0 bearish classifications. These labels summarize filing attributes; they are not recommendations, probabilities, or evidence of future price direction. There were 7 insider transactions (Form 4) in this period.

HRGN Filing Activity Snapshot 2025-07-01 — 2026-09-25

Insider Transactions (Form 4)

5 buys vs 0 sells

Net insider buying in this period — more purchases than sales reported.

Largest Form 144 Filing

$394.5K

He Junli (Director, CEO) · 2026-09-25

368,630 shares · Form 4

Insider Transactions 7 · Forms 3, 4 and 5

A Form 4 is filed within two business days of a company insider — an officer, a director, or a holder of more than ten percent of the stock — changing their position in the shares. All 7 filings in this group are Form 4s for Harvard Apparatus Regenerative Technology Inc.

The difficulty with reading these filings as a group is that a single form type covers transactions that mean entirely different things. An executive spending their own money to buy stock and an executive having shares withheld to pay tax on a vesting grant both appear as a Form 4. Every filing below is therefore tagged with the nature of the underlying transaction, taken from the transaction code reported on the form itself.

Across the 7 insider filings shown, the breakdown is 5 open-market purchase and 2 compensation award. 5 of them involved a discretionary open-market trade; the rest are compensation and administrative mechanics.

What each transaction type means

Open-market purchase ×5: The insider bought shares on the open market with their own money. This is the only Form 4 category that requires a discretionary cash outlay at the prevailing price.
Compensation award ×2: Shares were granted as compensation rather than purchased. No cash changed hands, so the filing reflects a pay decision by the company, not a judgement about the price.

Form 4 Open-market purchase Insider Buying 2026-09-25

HRGN insider He Junli (Director, CEO) bought 368,630 shares (~$394.5K)

He Junli, listed as Director, CEO at Harvard Apparatus Regenerative Technology, Inc., reported an open-market purchase of 368,630 HRGN shares in a Form 4 filing. Insider buying is often treated as a bullish signal because company insiders are committing their own capital.

The insider bought shares on the open market with their own money. This is the only Form 4 category that requires a discretionary cash outlay at the prevailing price.

Transactions reported on this filing
Code	Nature	Shares	Price	Value
`C`	Derivative conversion	683,725	$1.05	$717.9K
`P`	Open-market purchase	361,905	$1.05	$380.0K
`P`	Open-market purchase	6,725	$2.15	$14.5K
`C`	Derivative conversion derivative · Bridge Note (04/14/2026)	310,000	—	—
`C`	Derivative conversion derivative · Bridge Note (05/13/2026)	205,378	—	—
`C`	Derivative conversion derivative · Bridge Note (07/16/2026)	202,533	—	—

Filing: Form 4 (Insider Transaction) Insider: He Junli (Director, CEO) Shares: 368,630 Est. Value: $394.5K

View on SEC EDGAR → Open Filing Document →

Form 4 Compensation award Tax / Compensation Filing 2026-08-11

HRGN insider Form 4 filed for equity award, exercise, or tax withholding

He Junli (Director, CEO) filed a Form 4 covering compensation-related activity such as stock awards, option exercises, conversions, or tax withholding. These filings are usually neutral.

Shares were granted as compensation rather than purchased. No cash changed hands, so the filing reflects a pay decision by the company, not a judgement about the price.

Transactions reported on this filing
Code	Nature	Shares	Price	Value
`A`	Compensation award derivative · Nonqualified Stock Option (right to buy), time-based tranche	600,000	—	—
`A`	Compensation award derivative · Nonqualified Stock Option (right to buy), performance-based	600,000	—	—

Filing: Form 4 (Insider Transaction) Insider: He Junli (Director, CEO)

View on SEC EDGAR → Open Filing Document →

Form 4 Open-market purchase Insider Buying 2025-12-01

HRGN insider He Junli (Director, CEO) bought 3,000 shares (~$5.1K)

He Junli, listed as Director, CEO at Harvard Apparatus Regenerative Technology, Inc., reported an open-market purchase of 3,000 HRGN shares in a Form 4 filing. Insider buying is often treated as a bullish signal because company insiders are committing their own capital.

The insider bought shares on the open market with their own money. This is the only Form 4 category that requires a discretionary cash outlay at the prevailing price.

Transactions reported on this filing
Code	Nature	Shares	Price	Value
`P`	Open-market purchase	3,000	$1.70	$5.1K

Filing: Form 4 (Insider Transaction) Insider: He Junli (Director, CEO) Shares: 3,000 Est. Value: $5.1K

View on SEC EDGAR → Open Filing Document →

Form 4 Open-market purchase Insider Buying 2025-10-01

HRGN insider He Junli (Director, CEO) bought 300 shares (~$594.00)

He Junli, listed as Director, CEO at Harvard Apparatus Regenerative Technology, Inc., reported an open-market purchase of 300 HRGN shares in a Form 4 filing. Insider buying is often treated as a bullish signal because company insiders are committing their own capital.

The insider bought shares on the open market with their own money. This is the only Form 4 category that requires a discretionary cash outlay at the prevailing price.

Transactions reported on this filing
Code	Nature	Shares	Price	Value
`P`	Open-market purchase	300	$1.98	$594.00

Filing: Form 4 (Insider Transaction) Insider: He Junli (Director, CEO) Shares: 300 Est. Value: $594.00

View on SEC EDGAR → Open Filing Document →

Form 4 Open-market purchase Insider Buying 2025-09-24

HRGN insider He Junli (Director, CEO) bought 11,225 shares (~$20.8K)

He Junli, listed as Director, CEO at Harvard Apparatus Regenerative Technology, Inc., reported an open-market purchase of 11,225 HRGN shares in a Form 4 filing. Insider buying is often treated as a bullish signal because company insiders are committing their own capital.

The insider bought shares on the open market with their own money. This is the only Form 4 category that requires a discretionary cash outlay at the prevailing price.

Transactions reported on this filing
Code	Nature	Shares	Price	Value
`P`	Open-market purchase	11,225	$1.85	$20.8K

Filing: Form 4 (Insider Transaction) Insider: He Junli (Director, CEO) Shares: 11,225 Est. Value: $20.8K

View on SEC EDGAR → Open Filing Document →

Form 4 Open-market purchase Insider Buying 2025-09-02

HRGN insider He Junli (Director, CEO) bought 4,050 shares (~$7.0K)

He Junli, listed as Director, CEO at Harvard Apparatus Regenerative Technology, Inc., reported an open-market purchase of 4,050 HRGN shares in a Form 4 filing. Insider buying is often treated as a bullish signal because company insiders are committing their own capital.

The insider bought shares on the open market with their own money. This is the only Form 4 category that requires a discretionary cash outlay at the prevailing price.

Transactions reported on this filing
Code	Nature	Shares	Price	Value
`P`	Open-market purchase	4,050	$1.72	$7.0K

Filing: Form 4 (Insider Transaction) Insider: He Junli (Director, CEO) Shares: 4,050 Est. Value: $7.0K

View on SEC EDGAR → Open Filing Document →

Form 4 Compensation award Tax / Compensation Filing 2025-07-01

HRGN insider Form 4 filed for equity award, exercise, or tax withholding

Zhang Mao (Director) filed a Form 4 covering compensation-related activity such as stock awards, option exercises, conversions, or tax withholding. These filings are usually neutral.

Shares were granted as compensation rather than purchased. No cash changed hands, so the filing reflects a pay decision by the company, not a judgement about the price.

Transactions reported on this filing
Code	Nature	Shares	Price	Value
`A`	Compensation award derivative · Stock Option (right to buy)	18,590	—	—
`A`	Compensation award derivative · Stock Option (right to buy)	15,227	—	—

Filing: Form 4 (Insider Transaction) Insider: Zhang Mao (Director)

View on SEC EDGAR → Open Filing Document →

Material Events 8 · Form 8-K

An 8-K reports a material event in the window between scheduled reports. There are 8 in this period for Harvard Apparatus Regenerative Technology Inc. Each 8-K names the item number it is filed under, and that number is the fastest way to tell a routine disclosure from a consequential one.

Item 2.02 is an earnings release, Item 5.02 is a change of directors or officers, and Item 1.01 or 2.01 covers a material agreement or a completed acquisition. Item 7.01 and Item 8.01 are the general-purpose disclosure items and carry no fixed meaning on their own.

Form 8-K Material Company Update 2026-09-14

HRGN filed 8-K — material company event

Harvard Apparatus Regenerative Technology, Inc. filed an 8-K with the SEC reporting a material event. Summary unavailable — view the original SEC filing for the full text.

Filing: 8-K (Material Event)

View on SEC EDGAR → Open Filing Document →

Form 8-K Material Company Update 2026-08-03

HRGN filed 8-K — material company event

Harvard Apparatus Regenerative Technology, Inc. filed an 8-K with the SEC reporting a material event. Summary unavailable — view the original SEC filing for the full text.

Filing: 8-K (Material Event)

View on SEC EDGAR → Open Filing Document →

Form 8-K/A Amended Material Company Update 2026-08-03

HRGN filed amended 8-K — material company event

Harvard Apparatus Regenerative Technology, Inc. filed an amended 8-K with the SEC reporting a material event. Summary unavailable — view the original SEC filing for the full text.

Filing: 8-K/A (Material Event Amendment)

View on SEC EDGAR → Open Filing Document →

Form 8-K Material Company Update 2026-06-24

HRGN filed 8-K — material company event

Harvard Apparatus Regenerative Technology, Inc. filed an 8-K with the SEC reporting a material event. Summary unavailable — view the original SEC filing for the full text.

Filing: 8-K (Material Event)

View on SEC EDGAR → Open Filing Document →

Form 8-K Material Company Update 2026-04-28

HRGN filed 8-K — material company event

Harvard Apparatus Regenerative Technology, Inc. filed an 8-K with the SEC reporting a material event. Summary unavailable — view the original SEC filing for the full text.

Filing: 8-K (Material Event)

View on SEC EDGAR → Open Filing Document →

Form 8-K Material Company Update 2026-04-15

HRGN filed 8-K — material company event

Harvard Apparatus Regenerative Technology, Inc. filed an 8-K with the SEC reporting a material event. Summary unavailable — view the original SEC filing for the full text.

Filing: 8-K (Material Event)

View on SEC EDGAR → Open Filing Document →

Form 8-K Material Company Update 2026-01-06

HRGN filed 8-K — material company event

Harvard Apparatus Regenerative Technology, Inc. filed an 8-K with the SEC reporting a material event. Summary unavailable — view the original SEC filing for the full text.

Filing: 8-K (Material Event)

View on SEC EDGAR → Open Filing Document →

Form 8-K Material Company Update 2025-07-14

HRGN filed 8-K — material company event

Harvard Apparatus Regenerative Technology, Inc. filed an 8-K with the SEC reporting a material event. Summary unavailable — view the original SEC filing for the full text.

Filing: 8-K (Material Event)

View on SEC EDGAR → Open Filing Document →

Periodic Reports 5 · Forms 10-K and 10-Q

The periodic reports are where the audited and reviewed financial statements live. This period contains 1 annual report (10-K) and 4 quarterly reports (10-Q) for Harvard Apparatus Regenerative Technology Inc.

The two are not equivalent in weight. A 10-K is audited by an external firm and includes the full risk factor disclosure, business description and management discussion; a 10-Q is unaudited, reviewed rather than examined, and much shorter. When a figure in a quarterly report is later revised, the annual report is usually where the correction appears.

An amended report — 10-K/A or 10-Q/A — restates or corrects something in the original filing, and is worth reading against the version it replaces.

Form 10-Q Quarterly Report 2026-08-13

HRGN filed Quarterly Report (10-Q)

Harvard Apparatus Regenerative Technology, Inc. filed its quarterly report with the SEC. This report includes unaudited financial statements and management discussion for the quarter.

Filing: 10-Q (Quarterly Report)

View on SEC EDGAR → Open Filing Document →

Form 10-Q Quarterly Report 2026-05-13

HRGN filed Quarterly Report (10-Q)

Harvard Apparatus Regenerative Technology, Inc. filed its quarterly report with the SEC. This report includes unaudited financial statements and management discussion for the quarter.

Filing: 10-Q (Quarterly Report)

View on SEC EDGAR → Open Filing Document →

Form 10-K Annual Report 2026-03-19

HRGN filed Annual Report (10-K)

Harvard Apparatus Regenerative Technology, Inc. filed its annual report with the SEC. This report includes audited financial statements, business overview, risk factors, and management discussion.

Filing: 10-K (Annual Report)

View on SEC EDGAR → Open Filing Document →

Form 10-Q Quarterly Report 2025-11-07

HRGN filed Quarterly Report (10-Q)

Harvard Apparatus Regenerative Technology, Inc. filed its quarterly report with the SEC. This report includes unaudited financial statements and management discussion for the quarter.

Filing: 10-Q (Quarterly Report)

View on SEC EDGAR → Open Filing Document →

Form 10-Q Quarterly Report 2025-08-11

HRGN filed Quarterly Report (10-Q)

Harvard Apparatus Regenerative Technology, Inc. filed its quarterly report with the SEC. This report includes unaudited financial statements and management discussion for the quarter.

Filing: 10-Q (Quarterly Report)

View on SEC EDGAR → Open Filing Document →

How we classify Harvard Apparatus Regenerative Technology Inc.'s filings

Straight from EDGAR

Each displayed record links to an original source document. StrongBuyAnalytics provides navigation and brief excerpts or summaries, not the filing itself. Parsing may omit context or contain errors, so read the original document in full.

Transaction codes, not guesswork

The nature shown on each insider filing comes from the transaction code the filer entered on the form itself — P for an open-market purchase, A for a compensation award, F for shares withheld to pay tax, M for an option exercise. Where one filing contains several codes, the transaction table lists them line by line.

Why the distinction matters

Insider activity is routinely summarised as buying or selling, which flattens together decisions that mean very different things. Shares withheld for tax on a vesting grant are an automatic administrative step; shares bought on the open market are someone committing their own money at the current price.

What this page does not tell you

A filing records what happened, not why. Form 4 does not always disclose whether a sale was executed under a pre-arranged Rule 10b5-1 plan, and no single filing is a basis for a decision on HRGN. Read these alongside the fundamentals rather than in isolation.

Frequently Asked Questions — HRGN SEC Filings

More Tools for HRGN

HRGN Full Stock Analysis HRGN Live Chart Institutional Ownership Earnings Calendar Options Flow Scanner Semiconductor Demand Zone Tracker Sector Scanner Browse All Stocks

Want deeper HRGN analysis?

View valuation, growth metrics, the rule-based stock-page score, demand zones, peer comparison, and more — all on the HRGN stock analysis page.

HRGN Full Analysis

Publisher, sources & limitations — September 15, 2026. StrongBuyAnalytics provides navigation and brief excerpts or summaries for educational use. Original filings remain at SEC EDGAR or other displayed source links; StrongBuyAnalytics does not author them. Filing dates are source dates, not publication dates for this page. Coverage can be delayed, incomplete, amended, or unavailable because of SEC/source availability, parsing, caching, or outages. Verify every material statement in the original filing.

Data Sources · Methodology · AI Disclosure · Corrections Policy · Disclaimer